Acarbose belongs to the alpha-glucosidase inhibitors and other hypoglycemic drugs, it is mainly through slowing down the intestinal absorption of carbohydrates, so as to achieve the effect of reducing and controlling postprandial blood sugar. The effect of this hypoglycemic drug is also good, the safety is relatively high. It should be noted that the patients using it need to be mainly postprandial blood glucose increase; dietary habits should be carbohydrate-based food, so that the case of taking acarbose will have a better effect. Clinical experiments have some evidence-based medicine, we will find: first, the applicable population of acarbose is very wide. Second, Acarbose can reduce the risk of hypoglycemia before the next meal by slowing down the absorption of carbohydrates, while at the same time reducing blood sugar fluctuations. Thirdly, it can have some cardiovascular protective effect on patients with diabetes, possibly, although this protective effect is not yet direct evidence that has been found by evidence-based medicine. At present, we are more concerned about, is that acarbose can also increase the number of bifidobacteria in the body of diabetic patients, change the site of glucose absorption in the intestinal tract, that is, in the upper part of the intestinal tract can impede the absorption of glucose, so that some of the oligosaccharides into the intestinal tract of the lower part of the intestinal tract, stimulate the intestinal endocrine cells, but also can play a number of indirect roles.